Exemestane is an aromatase inactivator presently approved by the FDA for the treatment of breast cancer. This drug was studied in a large randomized clinical trial for the prevention of breast cancer. The results of this study were published in the June 23 issue of the NEJM. Exemestane reduced the relative incidence of invasive breast cancer by 65%, in postmenopausal women with moderate risk of developing breast cancer. The benefit with this drug was accomplished without any significant serious toxicities.
Breast Cancer is the second most common cause of cancer death in the United States. This new addition will be additional ammunition, in the fight against breast cancer